News

Rezvilutamide Improves Survival vs Bicalutamide in Metastatic Hormone-Sensitive Prostate Cancer

10/27/2022

Allison Casey

In 2 interim analyses from the phase 3 CHART trial, rezvilutamide, a novel androgen-receptor inhibitor, significantly improved radiographic PFS and OS vs bicalutamide for patients with high-volume, metastatic, hormone-sensitive prostate...

In 2 interim analyses from the...

10/27/2022

Oncology

News

Continuing Enzalutamide After Progression Improves PFS in Metastatic Castration Resistant Prostate Cancer: PRESIDE Study

10/27/2022

Allison Casey

Results from the phase 3 PRESIDE study show that continuing enzalutamide with docetaxel and ADT after progression of metastatic castration-resistant prostate cancer is associated with improved PFS compared to placebo.

Results from the phase 3 PRESIDE...

10/27/2022

Oncology

News

FDA Approves Oral Darolutamide Tablets for Patients With Metastatic Hormone-Sensitive Prostate Cancer

08/08/2022

Allison Casey

On August 5, 2022, the FDA approved darolutamide tablets, taken orally, twice daily, in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

On August 5, 2022, the FDA...

08/08/2022

Oncology

Conference Coverage

LuPSMA vs Cabazitaxel for Metastatic Castration–Resistant Prostate Cancer: OS Outcomes From the TheraP Trial

06/06/2022

LuPSMA is associated with lower adverse events, higher response rates, improved patient-reported outcomes, and similar OS vs cabazitaxel for patients with metastatic castration–resistant prostate cancer who progress after docetaxel.

LuPSMA is associated with lower...

06/06/2022

Oncology

Conference Coverage

LuPSMA vs Cabazitaxel for Metastatic Castration–Resistant Prostate Cancer: OS Outcomes From the TheraP Trial

06/06/2022

LuPSMA is associated with lower...

06/06/2022

Oncology

Conference Coverage

Bicalutamide vs Novel Androgen Receptor Inhibitor for Metastatic Hormone–Sensitive Prostate Cancer

06/06/2022

Allison Casey

Novel oral androgen receptor inhibitor, SHR3680, significantly improved rPFS in patients with metastatic hormone–sensitive prostate cancer compared to bicalutamide, according to results from an interim analysis of the phase 3 CHART trial.

Novel oral androgen receptor...

06/06/2022

Oncology

Conference Coverage

Bicalutamide vs Novel Androgen Receptor Inhibitor for Metastatic Hormone–Sensitive Prostate Cancer

06/06/2022

Allison Casey

Novel oral androgen receptor...

06/06/2022

Oncology

Conference Coverage

Enzalutamide Added to Testosterone Suppression Provides OS Benefit in Metastatic Hormone–Sensitive Prostate Cancer

06/05/2022

Allison Casey

The addition of enzalutamide to testosterone suppression provides a clinically meaningful OS benefit over a conventional non-steroidal anti-androgen for patients with metastatic hormone-sensitive prostate cancer.

The addition of enzalutamide to...

06/05/2022

Oncology

Conference Coverage

Enzalutamide Added to Testosterone Suppression Provides OS Benefit in Metastatic Hormone–Sensitive Prostate Cancer

06/05/2022

Allison Casey

The addition of enzalutamide to...

06/05/2022

Oncology

News

Observation vs MRI Screening and Pre-emptive Treatment for Spinal Cord Compression in Patients With Prostate Cancer and Spinal Metastases

04/27/2022

John Otrompke

Routine MRI screening and pre-emptive treatment for malignant clinical spinal cord compression is not warranted in patients with asymptomatic castration-resistant prostate cancer and spinal metastases, according to results from the phase 3...

Routine MRI screening and...

04/27/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology